Green Cross Corporation

What Green Cross Corporation does

Green Cross Corporation (GC Holdings / GC; ticker 006280.KS) is a South Korea-based publicly traded holding company that operates a 40-affiliate global total healthcare group spanning biopharmaceuticals, plasma derivatives, vaccines, rare disease treatments, cell and gene therapies, in-vitro diagnostics, consumer health, and digital healthcare. Founded in 1967 and headquartered in Yongin-si (Giheung-gu), the group's core operating entity GC Biopharma manufactures and markets plasma-derived products including the IVIG brand Alyglo (US-launched 2024), the world's first antibiotic-free varicella vaccine BARYCELA using the proprietary MAV/06 strain (WHO PQ-certified 2023), and rare disease therapies such as Hunterase (Hunter syndrome) and Greenegene F (hemophilia A). The technology stack spans an mRNA-LNP drug delivery platform, AI-based RNA design through Mogam Institute, bispecific ADCs (EGFR x cMET), and an in-vivo CAR-T program developed with Appclone, supported by Asia's largest cell therapy manufacturing facility (GC Cell Center) and Asia's #1 EMR system (GC MediAI, serving 25,000+ Korean clinics).

Revenue is generated across multiple streams: enterprise field sales to hospitals, clinics, blood centers, and government health agencies; international public procurement (WHO/UNICEF) for WHO PQ-certified vaccines; co-development licensing arrangements (Hanmi Pharmaceutical for Fabry disease GC1134A, Canvera for ADC GC1148A, Appclone for in-vivo CAR-T, ST Pharm for AI-RNA); CDMO and central lab services through GC Cell and GCCL; and direct-to-consumer sales of health functional foods and placenta-extract products via GC Wellbeing and Ernisty online/retail channels. Distribution leverages wholly-owned regional subsidiaries in the US (Fort Lee, San Antonio, San Diego, Newark, Seattle, Irvine), China (Huainan manufacturing), Japan (Tokyo), and Brazil (São Paulo), giving GC regulatory-anchored access to North America, Latin America, and Asia-Pacific markets.

Name

Green Cross Corporation

Legal name

주식회사 녹십자홀딩스

Website

https://gccorp.com

Company type

Public

Founded year

1969

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Green Cross Corporation (GC Holdings) is a South Korean publicly traded healthcare holding company operating 40 affiliates that develop, manufacture, and commercialize plasma derivatives, vaccines (BARYCELA, MAV/06 strain), rare disease therapies, cell and gene therapies, diagnostics, and consumer health products across Korea, the US, China, Japan, and Brazil.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511), Food (Health) Supplement Retailers (456191)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industry

Health & Wellness (Vitamins, Supplements, OTC) DTC (CRAFACAC)

Keywords

• Biopharmaceutical manufacturing
• Plasma derivative products
• Vaccine development
• Cell and gene therapy
• In vitro diagnostics

Headquarters

HQ city

Giheung

HQ country

South Korea

HQ region

Asia

Offices18 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Plasma Derivatives (Blood Products): GC Biopharma's core revenue driver, including intravenous immunoglobulin (IVIG) products such as Alyglo (ALYGLO, GC5131A), albumin, coagulation factors, and other plasma-derived therapeutics. Manufactured at GMP-certified Ochang plant.
2. Vaccines: Sales of varicella vaccines (BARYCELA, using MAV/06 strain), quadrivalent influenza vaccine (GCFLU Quadrivalent), COVID-19 vaccine, and other pediatric/adult vaccines. Includes WHO PQ-certified products for global public procurement markets.
3. Rare Disease Treatments: High-value specialty pharmaceuticals including Hunter syndrome treatment (Hunterase/Idursulfase), Fabry disease treatment (GC1134A/HM15421, co-developed with Hanmi Pharmaceutical), and other ultra-rare disease therapeutics.
4. Cell and Gene Therapies: Revenue from CAR-NK cell therapy pipeline (via Artiva Biotherapeutics), cell therapy CDMO services from GC Cell's Asia's largest cell therapy manufacturing facility (Cell Center), and future in vivo CAR-T products.
5. In Vitro Diagnostics and Medical Devices: GC MS, GC Medis, GCCL, and GC Genome generate revenue from diagnostic reagents, point-of-care testing devices (blood glucose, HbA1c, lactic acid biosensors), clinical trial lab services, and genomic testing services.
6. Consumer Health Products: Health functional foods, nutritional supplements, placenta extracts, and wellness products sold through GC Wellbeing and Ernisty to individual consumers via online and retail channels.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

Green Cross Corporation (GC Holdings) is a Korean healthcare conglomerate operating through 40 affiliates (25 domestic, 15 overseas) that develops, manufactures, and commercializes plasma derivatives (IVIG, albumin), vaccines (varicella, influenza, hemorrhagic fever), rare disease treatments (Hunter syndrome, hemophilia, Fabry disease), and innovative therapeutics including mRNA-LNP vaccines, bispecific ADCs, and in vivo CAR-T cell therapies. The group also provides in vitro diagnostics, clinical trial lab services, consumer health functional foods, digital healthcare platforms, and cell therapy CDMO services through dedicated subsidiaries.

Product overview

GC (Green Cross Corporation / 녹십자홀딩스) is a biotech-based global total healthcare group encompassing disease prevention, diagnosis, treatment, medical devices, and wellness services across 40 affiliates. The portfolio includes: (1) GC녹십자 (GC Biopharma) as the core pharmaceutical entity developing plasma derivatives, vaccines (BARYCELA, flu, hemorrhagic fever), rare disease treatments (Hunterase, Greenegene F), and innovative pipeline (mRNA vaccines, ADC, in vivo CAR-T); (2) GC Cell for cell/gene therapy with Asia's largest manufacturing facility; (3) Diagnostic companies (GC MS, GCCL, GC Genome, GC Medis, Genes Laboratories) providing IVD reagents, clinical lab services, and genomics; (4) Consumer health brands (GC Wellbeing, GC Care) for health functional foods and digital health; (5) Healthcare services (GC i-MED, GC Labs, Dr.GC clinic); (6) Research foundation (MOGAM Institute) pioneering AI-driven drug discovery; (7) Engineering (GCEM) for GMP facilities; (8) International subsidiaries in US, China, Japan, Brazil, and biotech investments globally.

Differentiator

Problem solved

Functional benefit

Brands

• THE FAB FIVE: GC녹십자의 5대 핵심 R&D 파이프라인 자산 (20% SCIG, mCOVID 백신, EBV 서브유닛 백신, 파브리병 치료제, EGFR X cMET ADC)
• MAV/06
• BARYCELA
• ALYGLO
• ALYGLO (알리글로)
• 헌터라제
• 그린진
• 인비보 카티
• INIBO (이니보)
• Broccoli365

Quantifiable outcome

• MAV/06 varicella vaccine: 99-100% seroconversion rate in clinical trials; adverse event incidence of 0.41-0.57 cases per 100,000 doses (lower than major global vaccines)
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and major.

• ST Pharm (에스티팜)coreStrategic or Co-development Partner · 18 June 2026Mogam Institute for Biomedical Research and ST Pharm signed a joint R&D agreement for AI-based RNA design and optimization technology. Mogam contributes its AI platform (generative AI, bio-foundation models) for RNA structure design; ST Pharm contributes its RNA drug development and manufacturing technology. The goal is to accelerate next-generation RNA therapeutic development by combining AI with RNA platform capabilities.
• Appclone (앱클론)coreStrategic or Co-development Partner · 17 June 2026GC Biopharma and Appclone signed a strategic MOU for joint development of next-generation in vivo CAR-T (Invivo CAR-T) therapy. GC contributes its mRNA-LNP platform and GMP manufacturing capabilities; Appclone contributes its proprietary CAR technology, T-cell-specific antibody assets, and extensive CAR clinical experience. The partnership aims to create an off-the-shelf CAR-T product that can be administered like a vaccine, enabling same-day treatment without patient cell extraction.
• Medicover Integrated Clinical Services (MICS)majorStrategic or Co-development Partner · 10 February 2026GCCL and MICS (part of Medicover, international healthcare and diagnostic services company) signed an MOU for multinational clinical trial services collaboration covering Europe, US, and Asia-Pacific regions. Key collaboration areas include clinical trial operations and sample analysis across regions; project management support; joint marketing and client development; and service competitiveness enhancement through test item alignment and improved analytical efficiency.
• OPIS (Optimus Integrated Services)majorStrategic or Co-development Partner · 15 January 2026GCCL and OPIS signed an MOU on the sidelines of the 44th Annual J.P. Morgan Healthcare Conference 2026 to expand collaboration and strengthen global clinical trial market position. The partnership combines OPIS's Europe-focused global CRO network with GCCL's clinical trial sample analysis expertise to deliver integrated and efficient clinical trial solutions spanning planning, sample analysis, and data management across Europe and Asia.
• Hanmi Pharmaceutical (한미약품)majorStrategic or Co-development Partner · 1 January 2026GC Biopharma and Hanmi Pharmaceutical are co-developing Fabry disease treatment (GC1134A/HM15421). The drug is undergoing Phase 1/2 clinical trials in the US, Korea, and Argentina. Hanmi contributes co-development funding and regional clinical trial support in Korea.
• Canvera Therapeutics (카나프테라퓨틱스)majorStrategic or Co-development Partner · 1 January 2026GC Biopharma and Canvera Therapeutics are co-developing EGFR x cMET bispecific ADC (GC1148A) for solid tumor treatment. Canvera contributes its bispecific ADC platform technology; GC contributes its antibody development and GMP manufacturing capabilities. The partnership aims to advance the dual-targeting ADC into preclinical and clinical development.
• Artiva BiotherapeuticscoreStrategic or Co-development Partner · 1 January 2019GC Cell (via its US subsidiary) established Artiva Biotherapeutics in San Diego in 2019 for NK cell therapy development and commercialization in the US market. Artiva operates as an NRDO (No Research Development Only) company, licensing GC Cell's CAR technology and NK cell therapy pipeline assets. GC Cell retains technology leadership while Artiva focuses on US clinical development and commercialization.
• Infectious Disease Research Institute (IDRI)coreStrategic or Co-development Partner · 1 January 2017Curevo (GC Group subsidiary, Seattle) collaborates with IDRI for vaccine research and development. IDRI is a globally recognized vaccine research institution; the partnership provides Curevo with specialized vaccine research expertise supporting its next-generation shingles vaccine clinical development program.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Iovance Biotherapeutics: US-based cell therapy company developing autologous tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Comparable to GC Cell as a pure-play cell therapy developer competing in the same oncology cell therapy market with GMP manufacturing scale.
• Samsung Biologics: Korean biopharma CDMO providing contract manufacturing services for biologics, including biosimilars and innovative therapeutics. Comparable to GC Biopharma as a major Korean-based biopharmaceutical company with global manufacturing and CDMO capabilities, though Samsung Biologics is significantly larger and more focused on contract manufacturing.
• Celltrion: Korean biopharmaceutical company specializing in biosimilars and innovative biologics with global commercial reach. Comparable to GC Biopharma as a major Korean biopharma with similar product portfolio (IVIG, vaccines) and international expansion ambitions across the same regulatory markets (US, EU, Japan).
• WuXi Biologics: Global biologics CDMO providing contract development and manufacturing services for monoclonal antibodies and biologics. Comparable to GC Cell's CDMO business given similar outsourced manufacturing service offering for biologics and cell therapies globally.
• Daewoong Pharmaceutical: Korean pharmaceutical company with biopharmaceutical manufacturing, OTC consumer products, and international operations. Comparable to GC Holdings as a diversified Korean pharma with overlapping business mix including prescription drugs, biologics, and consumer health.
• Yuhan Corporation: Korean pharmaceutical company with diversified portfolio spanning prescription drugs, OTC, consumer health, and international markets. Comparable to GC Holdings as a diversified Korean healthcare conglomerate with both pharmaceutical manufacturing and consumer health divisions.
• SK Bioscience: Korean vaccine developer and manufacturer with WHO PQ-certified products for global public procurement. Directly comparable to GC Biopharma's vaccine business given similar product mix (varicella, influenza, COVID-19), shared global public health customers (WHO, UNICEF), and overlapping pipeline focus.
• Hanmi Pharmaceutical: Korean pharmaceutical company with focus on innovative therapeutics including rare disease drugs and biologics. Directly comparable as a Korean rare disease player; notably, Hanmi is also a current co-development partner with GC on the Fabry disease treatment (GC1134A/HM15421).

Broad incumbents

• Takeda Pharmaceutical: Global pharmaceutical company with major rare disease and plasma-derived therapeutics franchises (post-Shire acquisition). Comparable to GC Biopharma as a rare disease and immunoglobulin player in the same global markets, but operating at substantially larger scale.
• CSL Behring: Global leader in plasma-derived therapeutics and rare disease treatments, and the dominant player in IVIG/SCIG markets. Comparable to GC Biopharma's plasma derivatives and IVIG (Alyglo) franchise, but operating at significantly greater scale globally and competing directly in the US immunoglobulin market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights8 records

Customer concentration

• Facebookfacebook.com/GC.bio
• Instagraminstagram.com/gc.bio/?igshid=YmMyMTA2M2Y%3D

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries25 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Green Cross Corporation